← Back to Home

Fewer Surgeries for Patients with Respiratory Papillomatosis: FDA Grants Accelerated Approval to First Plasmid DNA Immunotherapy

Voceryq offers a new option for adults undergoing repeated surgeries, but its approval is still based on a study of 32 people. Whether it can sustain a reduction in the burden of surgery will be answered by a longer-term confirmatory trial.

By SURL BioNews

For patients with recurrent respiratory papillomatosis, removing abnormal tissue growth often provides only a respite before the next surgery. On October 30, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Voceryq, developed by Inovio, to reduce the frequency of surgeries to remove papillomas in adults. It is the first plasmid DNA immunotherapy approved for marketing in the United States, adding another treatment option for this chronically recurring disease.

Recurrent respiratory papillomatosis (RRP) is associated with infection by human papillomavirus (HPV) types 6 and 11. Lesions often appear in the larynx and near the vocal cords, affecting the voice and, in severe cases, even obstructing breathing. Surgery can remove existing abnormal tissue growth, but the virus may persist in the tissue, leaving patients facing recurring lesions and surgeries for years.

Voceryq, formerly known as INO-3107, is designed to guide the immune system to recognize cells infected with the relevant HPV types. The therapy uses two plasmids carrying genetic instructions for viral antigens and for interleukin-12 (IL-12), which enhances the immune response, respectively. It is used with the CELLECTRA device, which delivers brief electrical pulses to help DNA enter cells. According to the company, patients first undergo surgical debulking of visible lesions, followed by a nine-week dosing regimen.

The RRP-001 study supporting the approval enrolled 32 adults. Of these, 26 had undergone at least three surgeries in the year before treatment and were included in the efficacy analysis; this group had a median of 4.5 surgeries in the preceding year. In the first year after treatment, 7 patients underwent no further surgeries to remove papillomas, representing approximately 27% of the efficacy analysis population. Here, “complete response” means that no surgery was needed for one year; it cannot be interpreted as clearance of the virus or a cure for the disease.

This result provides evidence for the possibility of reducing the burden of surgery for some patients, but the evidence still comes from a small, open-label study. The FDA regarded the improvement in surgery frequency as an intermediate clinical endpoint reasonably likely to predict clinical benefit and granted accelerated approval on that basis; continued approval may depend on whether subsequent research confirms the benefit. Common adverse reactions include injection site reactions, headache, fatigue, hypertension, nausea, and dizziness. The electroporation procedure itself may also cause brief muscle contractions and local pain.

According to the FDA approval letter, the confirmatory study must enroll at least 50 adult and pediatric patients and evaluate surgical interventions for at least three years after treatment. The company must submit a draft trial protocol by December 30, 2026, complete the study by December 30, 2031, and submit the final report by August 30, 2032. Including children in the study does not mean that this approval covers children; the current indication remains limited to adults.

Inovio expects to begin accepting orders and shipping in approximately 60 days, with a full commercial launch in the first quarter of 2027. Dow Jones Newswires also reported this timeline. For patients, the value of the new therapy will lie in more concrete everyday experiences: one fewer surgery, one fewer recovery period, and how long that improvement lasts. This approval opens access to treatment, while long-term follow-up will determine how many people it can help move beyond a course of repeated surgeries.

References

  1. U.S. Food and Drug Administration
  2. U.S. Food and Drug Administration
  3. INOVIO Pharmaceuticals, Inc. via PR Newswire
  4. Dow Jones Newswires via MarketScreener